Arteriosclerosis, Thrombosis, and Vascular Biology. 1995;15:893-902
© 1995 American Heart Association, Inc.
Articles |
Quantification of Plasminogen Activators and Their Inhibitors in the Aortic Vessel Wall in Relation to the Presence and Severity of Atherosclerotic Disease
From the Division of Hematology/Oncology, Department of Internal Medicine (T.P., M.S., J.K.), and the Institute of Pathology (K.W.S.), University of Münster (Germany), and the Gaubius Laboratory IVVO-TNO (J.J.E.), Leiden, the Netherlands.
Abstract Increased expression of plasminogen activator inhibitor–1 (PAI-1) has been demonstrated in the human atherosclerotic vessel wall and may contribute to the impaired plasma fibrinolytic capacity in patients at high risk of atherothrombotic events. In addition, the mural PA/plasmin system may have important pathobiologic functions during atherogenesis. We quantitatively analyzed PAs of the tissue type (TPA) and urokinase type (UPA), PAIs, and plasminogen in protein extracts from different layers of human aorta in relation to the presence and severity of atherosclerotic lesions. In comparison with normal control vessels, intimal and neointimal TPA concentrations were reduced in atherosclerotic aortas except in the necrotic core areas of advanced plaques, where TPA was mainly complexed to PAI-1 in extracellular matrix deposits. In the media, TPA antigen was higher in lesional segments and closely associated with smooth muscle cells. UPA antigen was increased in the intima of atherosclerotic lesions and colocalized with tissue-infiltrating macrophages and neointimal smooth muscle cells. By spectrophotometric assay, neither TPA nor UPA activity could be detected in intimal or medial extracts. PAI-1 concentrations increased significantly in the intima of atherosclerotic segments compared with adjacent uninvolved areas or control aortas. The immunohistochemical distribution of PAI-1 was similar to that observed for TPA. A large excess of PAI-1 over PA concentrations, particularly in the intimal layer, characterizes atherosclerotic lesions of the human aorta and suggests that PA action is locally confined and counterbalanced by enhanced PAI expression and accumulation.
Key Words: fibrinolysis • plasminogen activators • vessel wall • atherosclerosis • plasminogen activator inhibitors
This article has been cited by other articles:
 |
|
 |
|
  B. Fuhrman, J. Khateeb, M. Shiner, O. Nitzan, R. Karry, N. Volkova, and M. Aviram Urokinase Plasminogen Activator Upregulates Paraoxonase 2 Expression in Macrophages Via an NADPH Oxidase-Dependent Mechanism Arterioscler. Thromb. Vasc. Biol., July 1, 2008; 28(7): 1361 - 1367. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Demyanets, C. Kaun, K. Rychli, G. Rega, S. Pfaffenberger, T. Afonyushkin, V. N. Bochkov, G. Maurer, K. Huber, and J. Wojta The inflammatory cytokine oncostatin M induces PAI-1 in human vascular smooth muscle cells in vitro via PI 3-kinase and ERK1/2-dependent pathways Am J Physiol Heart Circ Physiol, September 1, 2007; 293(3): H1962 - H1968. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. J. Oliver, D. J. Webb, and D. E. Newby Stimulated Tissue Plasminogen Activator Release as a Marker of Endothelial Function in Humans Arterioscler. Thromb. Vasc. Biol., December 1, 2005; 25(12): 2470 - 2479. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Xiang, M. D. Schuster, T. Seki, P. Witkowski, S. Eshghi, and S. Itescu Downregulated Expression of Plasminogen Activator Inhibitor-1 Augments Myocardial Neovascularization and Reduces Cardiomyocyte Apoptosis After Acute Myocardial Infarction J. Am. Coll. Cardiol., August 2, 2005; 46(3): 536 - 541. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. M. Kairuz, M. N. Barber, C. R. Anderson, M. Kanagasundaram, G. R. Drummond, and R. L. Woods C-type natriuretic peptide (CNP) suppresses plasminogen activator inhibitor-1 (PAI-1) in vivo Cardiovasc Res, June 1, 2005; 66(3): 574 - 582. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Xiang, M. D. Schuster, T. Seki, A. A. Kocher, S. Eshghi, A. Boyle, and S. Itescu Down-regulation of Plasminogen Activator Inhibitor 1 Expression Promotes Myocardial Neovascularization by Bone Marrow Progenitors J. Exp. Med., December 20, 2004; 200(12): 1657 - 1666. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Sokabe, K. Yamamoto, N. Ohura, H. Nakatsuka, K. Qin, S. Obi, A. Kamiya, and J. Ando Differential regulation of urokinase-type plasminogen activator expression by fluid shear stress in human coronary artery endothelial cells Am J Physiol Heart Circ Physiol, November 1, 2004; 287(5): H2027 - H2034. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. J. Schneider, M. Hayes, M. Wadsworth, H. Taatjes, M. Rincon, D. J. Taatjes, and B. E. Sobel Attenuation of Neointimal Vascular Smooth Muscle Cellularity in Atheroma by Plasminogen Activator Inhibitor Type 1 (PAI-1) J. Histochem. Cytochem., August 1, 2004; 52(8): 1091 - 1099. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. I. Vulin and F. M. Stanley Oxidative Stress Activates the Plasminogen Activator Inhibitor Type 1 (PAI-1) Promoter through an AP-1 Response Element and Cooperates with Insulin for Additive Effects on PAI-1 Transcription J. Biol. Chem., June 11, 2004; 279(24): 25172 - 25178. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. E. Cozen, H. Moriwaki, M. Kremen, M. B. DeYoung, H. L. Dichek, K. I. Slezicki, S. G. Young, M. Veniant, and D. A. Dichek Macrophage-Targeted Overexpression of Urokinase Causes Accelerated Atherosclerosis, Coronary Artery Occlusions, and Premature Death Circulation, May 4, 2004; 109(17): 2129 - 2135. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H.-C. Chen and E. P. Feener MEK1,2 response element mediates angiotensin II--stimulated plasminogen activator inhibitor-1 promoter activation Blood, April 1, 2004; 103(7): 2636 - 2644. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. M. Razzaq, R. Bass, D. J. Vines, F. Werner, S. A. Whawell, and V. Ellis Functional Regulation of Tissue Plasminogen Activator on the Surface of Vascular Smooth Muscle Cells by the Type-II Transmembrane Protein p63 (CKAP4) J. Biol. Chem., October 24, 2003; 278(43): 42679 - 42685. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Falkenberg, C. Tom, M. B. DeYoung, S. Wen, R. Linnemann, and D. A. Dichek Increased expression of urokinase during atherosclerotic lesion development causes arterial constriction and lumen loss, and accelerates lesion growth PNAS, August 6, 2002; 99(16): 10665 - 10670. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. I. Vulin and F. M. Stanley A Forkhead/Winged Helix-related Transcription Factor Mediates Insulin-increased Plasminogen Activator Inhibitor-1 Gene Transcription J. Biol. Chem., May 31, 2002; 277(23): 20169 - 20176. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. J. Podor, D. Singh, P. Chindemi, D. M. Foulon, R. McKelvie, J. I. Weitz, R. Austin, G. Boudreau, and R. Davies Vimentin Exposed on Activated Platelets and Platelet Microparticles Localizes Vitronectin and Plasminogen Activator Inhibitor Complexes on Their Surface J. Biol. Chem., February 22, 2002; 277(9): 7529 - 7539. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Padro, R. M. Mesters, B. Dankbar, H. Hintelmann, R. Bieker, M. Kiehl, W. E. Berdel, and J. Kienast The catalytic domain of endogenous urokinase-type plasminogen activator is required for the mitogenic activity of platelet-derived and basic fibroblast growth factors in human vascular smooth muscle cells J. Cell Sci., January 5, 2002; 115(9): 1961 - 1971. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. B. DeYoung, C. Tom, and D. A. Dichek Plasminogen Activator Inhibitor Type 1 Increases Neointima Formation in Balloon-Injured Rat Carotid Arteries Circulation, October 16, 2001; 104(16): 1972 - 1971. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. M. Tabengwa, R. L. Benza, H. E. Grenett, and F. M. Booyse Hypertriglyceridemic VLDL Downregulates Tissue Plasminogen Activator Gene Transcription Through cis-Repressive Region(s) in the Tissue Plasminogen Activator Promoter in Cultured Human Endothelial Cells Arterioscler. Thromb. Vasc. Biol., June 1, 2000; 20(6): 1675 - 1681. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. A. Stoop, F. Lupu, and H. Pannekoek Colocalization of Thrombin, PAI-1, and Vitronectin in the Atherosclerotic Vessel Wall : A Potential Regulatory Mechanism of Thrombin Activity by PAI-1/Vitronectin Complexes Arterioscler. Thromb. Vasc. Biol., April 1, 2000; 20(4): 1143 - 1149. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Lopez, F. Peiretti, B. Bonardo, I. Juhan-Vague, and G. Nalbone Tumor Necrosis Factor alpha Up-regulates in an Autocrine Manner the Synthesis of Plasminogen Activator Inhibitor Type-1 during Induction of Monocytic Differentiation of Human HL-60 Leukemia Cells J. Biol. Chem., February 4, 2000; 275(5): 3081 - 3087. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. L. Bouchie, H. Hansen, and E. P. Feener Natriuretic Factors and Nitric Oxide Suppress Plasminogen Activator Inhibitor-1 Expression in Vascular Smooth Muscle Cells : Role of cGMP in the Regulation of the Plasminogen System Arterioscler. Thromb. Vasc. Biol., November 1, 1998; 18(11): 1771 - 1779. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Geppert, S. Graf, R. Beckmann, S. Hornykewycz, E. Schuster, B. R. Binder, and K. Huber Concentration of Endogenous tPA Antigen in Coronary Artery Disease : Relation to Thrombotic Events, Aspirin Treatment, Hyperlipidemia, and Multivessel Disease Arterioscler. Thromb. Vasc. Biol., October 1, 1998; 18(10): 1634 - 1642. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. H. A. Quax, J. M. Grimbergen, M. Lansink, A. H. F. Bakker, M.-C. Blatter, D. Belin, V. W. M. van Hinsbergh, and J. H. Verheijen Binding of Human Urokinase-Type Plasminogen Activator to Its Receptor : Residues Involved in Species Specificity and Binding Arterioscler. Thromb. Vasc. Biol., May 1, 1998; 18(5): 693 - 701. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y.-Q. Chen, M. Su, R. R. Walia, Q. Hao, J. W. Covington, and D. E. Vaughan Sp1 Sites Mediate Activation of the Plasminogen Activator Inhibitor-1 Promoter by Glucose in Vascular Smooth Muscle Cells J. Biol. Chem., April 3, 1998; 273(14): 8225 - 8231. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. M. Kanse, O. Benzakour, C. Kanthou, C. Kost, H. R. Lijnen, and K. T. Preissner Induction of Vascular SMC Proliferation by Urokinase Indicates a Novel Mechanism of Action in Vasoproliferative Disorders Arterioscler. Thromb. Vasc. Biol., November 1, 1997; 17(11): 2848 - 2854. [Abstract] [Full Text]
|
|
|
|
|
|
M. Tschopl, D. A. Tsakiris, G. A. Marbet, K.-H. Labs, and K. Jager Role of Hemostatic Risk Factors for Restenosis in Peripheral Arterial Occlusive Disease After Transluminal Angioplasty Arterioscler. Thromb. Vasc. Biol., November 1, 1997; 17(11): 3208 - 3214. [Abstract] [Full Text]
|
|
|
|
|
|
D. J. Schneider, M. A. Ricci, D. J. Taatjes, P. Q. Baumann, J. C. Reese, B. J. Leavitt, P. M. Absher, and B. E. Sobel Changes in Arterial Expression of Fibrinolytic System Proteins in Atherogenesis Arterioscler. Thromb. Vasc. Biol., November 1, 1997; 17(11): 3294 - 3301. [Abstract] [Full Text]
|
|
|
|
 |
|
 J.J. Emeis, Y. v. d. Eijnden-Schrauwen, C.M. v. d. Hoogen, W. d. Priester, A. Westmuckett, and F. Lupu An Endothelial Storage Granule for Tissue-Type Plasminogen Activator J. Cell Biol., October 6, 1997; 139(1): 245 - 256. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Padro, M. Steins, C.-X. Li, R. M Mesters, D. Hammel, H. H Scheld, and J. Kienast Comparative analysis of plasminogen activator inhibitor-1 expression in different types of atherosclerotic lesions in coronary arteries from human heart explants Cardiovasc Res, October 1, 1997; 36(1): 28 - 36. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Kauhanen, V. Siren, O. Carpen, A. Vaheri, M. Lepantalo, and R. Lassila Plasminogen Activator Inhibitor-1 in Neointima of Vein Grafts : Its Role in Reduced Fibrinolytic Potential and Graft Failure Circulation, September 16, 1997; 96(6): 1783 - 1789. [Abstract] [Full Text]
|
|
|
|
|
|
V. Ellis and S. A. Whawell Vascular Smooth Muscle Cells Potentiate Plasmin Generation by Both Urokinase and Tissue Plasminogen Activator-Dependent Mechanisms: Evidence for a Specific Tissue-Type Plasminogen Activator Receptor on These Cells Blood, September 15, 1997; 90(6): 2312 - 2322. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Peiretti, M.-C. Alessi, M. Henry, F. Anfosso, I. Juhan-Vague, and G. Nalbone Intracellular Calcium Mobilization Suppresses the TNF-{alpha}–Stimulated Synthesis of PAI-1 in Human Endothelial Cells : Indications That Calcium Acts at a Translational Level Arterioscler. Thromb. Vasc. Biol., August 1, 1997; 17(8): 1550 - 1560. [Abstract] [Full Text]
|
|
|
|
|
|
B. E. Sobel Potentiation of Vasculopathy by Insulin : Implications From an NHLBI Clinical Alert Circulation, May 1, 1996; 93(9): 1613 - 1615. [Full Text]
|
|
|
|
|
|
T. J. Podor, S. G. Shaughnessy, M. N. Blackburn, and C. B. Peterson New Insights into the Size and Stoichiometry of the Plasminogen Activator Inhibitor Type-1{middle dot}Vitronectin Complex J. Biol. Chem., August 11, 2000; 275(33): 25402 - 25410. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. J. Podor, C. B. Peterson, D. A. Lawrence, S. Stefansson, S. G. Shaughnessy, D. M. Foulon, M. Butcher, and J. I. Weitz Type 1 Plasminogen Activator Inhibitor Binds to Fibrin via Vitronectin J. Biol. Chem., June 23, 2000; 275(26): 19788 - 19794. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W.-Y. Zhang, I. Ishii, and H. S. Kruth Plasmin-mediated Macrophage Reversal of Low Density Lipoprotein Aggregation J. Biol. Chem., October 13, 2000; 275(42): 33176 - 33183. [Abstract] [Full Text] [PDF]
|
|